Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities.
about
Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial originDelineating the functional map of the interaction between nimotuzumab and the epidermal growth factor receptor.The emerging role of nimotuzumab in the treatment of non-small cell lung cancer.A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cellsA pilot study of nimotuzumab combined with cisplatin and 5-FU in patients with advanced esophageal squamous cell carcinomaBispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recyclingTuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumabStudy on chemotherapeutic sensitizing effect of nimotuzumab on different human esophageal squamous carcinoma cells.A collagen-binding EGFR antibody fragment targeting tumors with a collagen-rich extracellular matrix.Therapeutic approaches to target cancer stem cells.Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies.Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis.Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experienceNimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity.Targeting the epidermal growth factor receptor in solid tumor malignancies.Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities.Preclinical evaluation of radiolabelled nimotuzumab, a promising monoclonal antibody targeting the epidermal growth factor receptor.EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs.Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.Antitumor activity of nimotuzumab in combination with cisplatin in lung cancer cell line A549 in vitro.Prospective phase II trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer.
P2860
Q24645217-E22AA92D-CBB8-4C96-BB43-AFE081158AF3Q34223866-F7EE42E4-3D54-45FF-80FD-313CECF54D85Q34343043-15894FF5-7781-4236-833A-D5A3B61B23F8Q35153765-B7FA313C-AA9D-4753-BBB5-4B31859EB68BQ35667892-65CA1BBF-5CCC-4702-A264-7C9A3AB8C13AQ35842099-92C6E5F9-7811-40C0-89D4-4440C00B477AQ36218880-90BE9E97-4753-4C47-A994-13FF260E3047Q36285551-17AA3551-5F39-4EA9-959F-87F553E3B880Q36524485-130E540B-2610-4C06-AB67-22FFEAB7C600Q36587717-72EB5E81-9226-4652-8B8E-BCD8B7A21BCCQ37137412-C78F2E7F-2C4E-4B88-8944-DDA48FFBB98CQ37141964-3FE5EC71-F716-4C29-9DE7-C5DAD217A408Q37269328-FF37A487-504E-4ED5-A55C-683FFFA3B71EQ37362948-C3592D2D-014D-4D3D-9AFB-33093F482171Q37558534-1F6681B6-0B4B-4AEC-8713-8E6FCD60CDD1Q37990044-2E54B100-30A9-4111-A6F9-C5BBE38E50BBQ38127413-BF5F5477-F232-47A5-9E33-10D6CDE4C383Q39052926-E8740F50-F492-4797-8E97-DA0065730419Q41855293-C7107159-13BA-4E56-B5C8-E1AD4695B401Q44656784-53477BC3-8EBC-4647-8783-519AFFDDD4D1Q52725862-16BB6255-08F3-43D8-9FE0-EA37782ECEEAQ53651597-C76600D3-7558-4F97-88AD-52FF10B4FEF6
P2860
Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Biological activity in vitro o ...... ies with different affinities.
@en
type
label
Biological activity in vitro o ...... ies with different affinities.
@en
prefLabel
Biological activity in vitro o ...... ies with different affinities.
@en
P2093
P356
P1433
P1476
Biological activity in vitro o ...... dies with different affinities
@en
P2093
Ana E Batista
Arlhee Diaz Miqueli
Beatriz Garcia
Enrique Montero
Ruby Alonso
Teresita Badia
P304
P356
10.1089/HYB.2007.0516
P577
2007-12-01T00:00:00Z